大摩发布研报称，英矽智能是AIDD领域的领先者，在技术验证与应用方面均取得实质性进展。其化学 模型的执行力支撑其可重复的"1-to-N"创新创造引擎；随着生物学模型的人体验证逐步显现，其潜在上 行弹性有望在整个行业进入广泛AIDD采用期时得到进一步释放。 消息面上，继2025年7月获得逾2340万港元的开发和监管里程碑付款后，英矽智能在双方合作项目 MEN2501完成I期临床试验首例患者给药后，再次获得美纳里尼集团就该项目支付的3900万港元里程碑 付款。MEN2501是一款具备高度差异化的KIF18A抑制剂，由英矽智能生成式AI引擎设计与优化，用于 染色体不稳定性实体瘤治疗。 英矽智能(03696)午后涨超10%，截至发稿，涨10.14%，报68.45港元，成交额1.82亿港元。 ...

智通财经APP获悉，英矽智能(03696)午后涨超10%，截至发稿，涨10.14%，报68.45港元，成交额1.82亿 港元。 消息面上，继2025年7月获得逾2340万港元的开发和监管里程碑付款后，英矽智能在双方合作项目 MEN2501完成I期临床试验首例患者给药后，再次获得美纳里尼集团就该项目支付的3900万港元里程碑 付款。MEN2501是一款具备高度差异化的KIF18A抑制剂，由英矽智能生成式AI引擎设计与优化，用于 染色体不稳定性实体瘤治疗。 大摩发布研报称，英矽智能是AIDD领域的领先者，在技术验证与应用方面均取得实质性进展。其化学 模型的执行力支撑其可重复的 "1-to-N" 创新创造引擎；随着生物学模型的人体验证逐步显现，其潜在 上行弹性有望在整个行业进入广泛AIDD采用期时得到进一步释放。 ...

Core Viewpoint - Insilico Medicine is set to become the largest biotech IPO in the Hong Kong market in 2025, with significant backing from prominent investors like Qiming Venture Partners, Warburg Pincus, Temasek, Hillhouse, and Sequoia China [2] Investment Background - Qiming Venture Partners led Insilico Medicine's Series B financing in 2019 and has since increased its stake, holding approximately 7% before the IPO [2] - The investment was driven by the belief that AI will profoundly change drug development pathways and efficiency [2][4] - Insilico Medicine's collaboration with WuXi AppTec in 2018 resulted in the rapid identification of a small molecule lead compound targeting DDR1 in just 46 days, showcasing the potential of AI in drug discovery [4] Company Development and Strategy - Insilico Medicine has established a pipeline of over 30 innovative projects across various therapeutic areas, including oncology, immunology, fibrosis, and metabolism [7] - The company has partnered with 13 of the top 20 pharmaceutical companies globally, generating potential revenue of $2 billion through pipeline licensing agreements [7][8] - The introduction of Dr. Ren Feng, a seasoned drug development expert, was facilitated by Qiming to strengthen the company's capabilities in drug development [5] Future Expectations - The increasing validation of Insilico Medicine's platform is expected to enhance its attractiveness as a partner for top international pharmaceutical companies [8] - There is an anticipation that AI will not only empower early-stage research but also significantly accelerate clinical development processes, allowing new drugs to reach patients sooner [2][8] - The company aims to expand the application of its AI-driven platform beyond preclinical stages to include clinical phases, enhancing efficiency in patient recruitment, clinical protocol writing, data analysis, and regulatory review [11] Industry Insights - Qiming Venture Partners has previously invested in Schrödinger, gaining insights into the AIDD sector, which has informed their investment strategy in Insilico Medicine [9][10] - The firm recognizes that merely providing software services in the AIDD space may lead to slow growth, prompting a focus on generating pipeline projects for scalability [10] - The collaboration between Qiming's medical innovation and technology investment teams has been crucial in identifying and supporting leading companies in the AI and healthcare sectors [10]